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The world urgently requires a new vaccine to combat the 
problem of tuberculosis (TB). The failure of BCG vaccine, the 
emergence of extensively drug-resistant TB  and the increasing 
global TB-related mortality has emphasised the urgent need to 
develop more effective TB vaccines to combat this scourge. The 
development of new genetic technology and the sequencing of 
the Mycobacterium tuberculosis genome in the late nineties have 
made the rational development of new TB vaccines a reality.
The ideal TB vaccine should be affordable, especially in the 
poorest countries of the world where it is most needed, and 
should be more cost-effective than BCG vaccine. It should 
be easily administered at or soon after birth, and be safe, 
immunogenic and effective at all ages and in all populations. It 
is unlikely that a single new vaccine candidate will meet all or 
even most of these requirements, and it is likely that more than 
one new vaccine will be needed. 
TB is a leading opportunistic infection in HIV-positive 
persons. New TB vaccines would therefore have to be safe, 
immunogenic and effective in this at-risk population as well. 
Recently the WHO has recommended that children who are 
known to be HIV positive, even if they are asymptomatic, 
should not be given BCG vaccine because of the high risk of 
possibly developing disseminated BCG disease.
TB vaccine strategies
From a public health perspective, delivering a vaccine prior 
to exposure to mycobacterial infection and preferably soon 
after birth makes most sense. In high-burden countries this 
pre-infection vaccination strategy will be the ideal option. A 
second option would be to use a new TB vaccine as a booster 
some time after neonatal BCG vaccination. A third option is to 
prevent disease by enhancing or boosting immunity in persons 
already infected, a post-infection vaccine strategy. This approach 
is attractive because more than 2 billion persons worldwide are 
already infected and therefore at risk of progression to disease. 
This is also an attractive option for countries with high rates 
of HIV, presuming that such a vaccine will be safe in these 
populations. A fourth option would be to use a vaccine as an 
adjunct to anti-TB treatment, to shorten therapy or reduce the 
risk of relapse, a therapeutic vaccine. This may be particularly 
relevant in situations where multidrug-resistant TB cases are 
common and in areas where TB control programmes are not 
managing to provide adequate sustainable care.
New candidate TB vaccines 
The last 15 years have seen a number of TB vaccine candidates 
progressing from concept to laboratory to preclinical studies 
and finally to clinical trials; more than 200 such candidates 
have been tested in animals. Currently 4 vaccine candidates 
are actively being evaluated in human clinical trials. These are 
MVA85A, Mtb72f, Aeras-402 and M. vaccae. There are other 
candidates, some of which are extremely promising, and these 
should be entering human clinical trials in the next year or two. 
All of the candidates developed to date have been shown to be 
as good as or superior to BCG in animal trials.  
MVA85A vaccine (Oxford University, UK)
This subunit recombinant vaccine consists of a specific 
mycobacterial protein antigen (Ag 85) expressed in a non-
replicating viral vector, MVA, a strain of the vaccinia virus. 
Phase I clinical studies in adults completed in Oxford and The 
Gambia have demonstrated safety and immunogenicity as 
measured by ex vivo interferon-gamma (IFN-γ) Elispot assay, 
which assesses specific T-cell responses to tuberculin purified 
protein derivative (PPD), antigen 85 and its constituent 
peptides. 
A phase II study in healthy, TB-naïve, HIV-uninfected adults 
and adolescents, half of them BCG-exposed, is ongoing at 
the South African Tuberculosis Vaccine Initiative (SATVI, see 
below) site near Cape Town. Preliminary results are promising. 
Additional South African studies, planned for  mid-2007, will 
test the vaccine’s safety and immunogenicity in HIV-infected, 
TB-infected and HIV-TB co-infected individuals, and then in 
168 healthy children and infants. 
Mtb72F (Glaxo Smith Klein Biologicals, Rixensart, 
Belgium)
Mtb72F is a combination of two immunogenic M. tuberculosis 
antigens, Mtb39a and Mtb32a, plus the adjuvants ASO2A or 
ASO1B.
In 2005, the vaccine entered a phase I clinical trial in 
healthy TB-uninfected adult volunteers in the USA. It was 
subsequently evaluated in Belgium in PPD-negative adult 
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volunteers. In both trials it was found to be immunogenic, safe 
and well tolerated. 
A newer formulation of the vaccine, M72, is currently 
undergoing clinical trials in Europe, with further trials planned 
for the SATVI site in South Africa in late 2007.
AERAS-402 (Aeras Global Tuberculosis Vaccine 
Foundation, Rockville, MD, USA)
This vaccine is intended for use as a boosting vaccine in BCG-
primed individuals. The vaccine is a serotype 35 adenovirus 
which is incapable of replicating and contains DNA that 
expresses a fusion protein created from three M. tuberculosis 
antigens: 85A, 85B and TB10.4. TB10.4 is a member of the 
ESAT-6 group of proteins found in M. tuberculosis culture 
supernatants which has been shown to be immunogenic. 
This vaccine has undergone phase I studies in the USA and 
has been shown to be safe. The first trial in South Africa is due 
to start at the SATVI site near Cape Town in mid-2007.
M. vaccae
M. vaccae is an environmental saprophyte, which is thought to 
have immunogenic properties which enhance the host immune 
response. It is has been tested as an adjunct in TB treatment 
rather than as a preventive vaccine. Its efficacy in preventing 
TB in HIV-positive persons is also being evaluated in a large 
Tanzanian clinical trial.       
Challenges to TB vaccine 
development
There are a number of obstacles to overcome in the 
development of new TB vaccines. These include the lack of a 
suitable animal model, especially a model mimicking latent or 
reactivation TB, the absence of a reliable surrogate marker of 
protection or a correlate of immune protection, the difficulty 
with field evaluation of TB vaccines, problems with defining 
clinical endpoints in paediatric practice and lack of resources. 
Given the magnitude of the problem worldwide, a global 
strategy is imperative to co-ordinate collaborative efforts to 
develop vaccines that are effective in reducing TB. Strategic 
investments made by the European Union, the National 
Institutes of Health, the Bill and Melinda Gates Foundation and 
other agencies and governments have gone a long way towards 
meeting the intended goal. However, significant additional 
resources and commitments are needed to support additional 
research, preclinical development, vaccine production and 
clinical trials. The Stop TB Working Group on New TB Vaccines 
has estimated that over $3 000 million will be needed to ensure 
that we get a new TB vaccine into the field by 2015.
South African TB Vaccine Initiative 
(SATVI) 
The main objectives of the SATVI, a research unit within the 
Institute of Infectious Diseases and Molecular Medicine at 
UCT, are to develop the capacity of our rural site in Worcester 
to do phase I to phase IV TB vaccine trials, to determine 
important epidemiological characteristics that are of relevance 
to TB in the area and to identify clinical, microbiological and 
immunological endpoints of key importance to all stages of 
vaccine trials. Our immunology studies aim to characterise the 
human host immune response to TB and BCG vaccination, to 
identify immune correlates of protection against TB induced by 
BCG vaccination, and to determine whether BCG vaccination is 
safe and immunogenic in HIV-infected children. Our flagship 
project, started in March 2001 and completed at the end of 
July 2006, showed in a randomised clinical trial equivalence in 
efficacy between percutaneous and intradermal Japanese BCG 
in preventing TB in 11 680 infants vaccinated at birth. Nested 
within this study is a case control study designed to identify 
correlates of immune protection. We are currently involved in 
testing a number of new TB vaccines in phase I and II studies. 
The work of SATVI is supported by a number of 
international donors including the Aeras Global TB Vaccine 
Foundation, the National Institutes for Heath, USA, the 
European Union and the Welcome Trust.
Conclusion 
The current BCG vaccine prevents the invasive complications 
of childhood TB, such as meningitis and miliary disease, but 
provides variable protection against adult pulmonary disease. 
Several new TB vaccines have demonstrated promising 
results in animal models; a number have gone into phase 
I clinical trials in humans and have been shown to be safe 
and immunogenic. It is anticipated that phase III trials will 
commence by 2009. Licensing of an effective new TB vaccine by 
2015 is thus a possibility. The introduction of new TB vaccines 
is seen as an essential part of the global strategy to eliminate 
TB by 2050.
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